KRYS – Krystal Biotech, Inc.
Krystal Biotech, Inc.KRYS
$134.53Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,887,741,952.00
EPSttm : 4.17
Krystal Biotech, Inc.
$134.53
3.51%$4.90Float Short %
9.58
Margin Of Safety %
72
Put/Call OI Ratio
0.48
EPS Next Q Diff
0.21
EPS Last/This Y
2.76
EPS This/Next Y
4.61
Price
134.53
Target Price
211.2
Analyst Recom
1.18
Performance Q
-10.27
Relative Volume
1.02
Beta
0.71
Ticker: KRYS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | KRYS | 168.97 | 0.43 | 0.00 | 4627 |
| 2025-04-15 | KRYS | 169.15 | 0.43 | 0.60 | 4628 |
| 2025-04-16 | KRYS | 164.7 | 0.42 | 0.05 | 4627 |
| 2025-04-17 | KRYS | 168.36 | 0.42 | 0.39 | 4616 |
| 2025-04-18 | KRYS | 168.57 | 0.42 | 0.36 | 4616 |
| 2025-04-21 | KRYS | 161.72 | 0.68 | 0.15 | 3370 |
| 2025-04-22 | KRYS | 167.8 | 0.68 | 2.19 | 3392 |
| 2025-04-23 | KRYS | 165.7 | 0.67 | 1.00 | 3405 |
| 2025-04-24 | KRYS | 168.96 | 0.78 | 0.08 | 5408 |
| 2025-04-25 | KRYS | 168.06 | 0.7799671592775 | 20 | 5420 |
| 2025-04-28 | KRYS | 169.73 | 0.77890932982917 | 0.66666666666667 | 5415 |
| 2025-04-29 | KRYS | 170.56 | 0.78 | 0.34 | 5415 |
| 2025-04-30 | KRYS | 169.54 | 0.77 | 1.83 | 5482 |
| 2025-05-01 | KRYS | 165.68 | 0.77 | 23.00 | 5480 |
| 2025-05-02 | KRYS | 165.89 | 0.76 | 2.00 | 5463 |
| 2025-05-05 | KRYS | 162.18 | 0.76 | 1.22 | 5466 |
| 2025-05-06 | KRYS | 139.73 | 0.77 | 0.98 | 5470 |
| 2025-05-07 | KRYS | 136.75 | 0.77 | 0.13 | 6904 |
| 2025-05-08 | KRYS | 137.17 | 0.57 | 0.26 | 6262 |
| 2025-05-09 | KRYS | 132.03 | 0.54 | 0.45 | 6355 |
| 2025-05-12 | KRYS | 139.44 | 0.49 | 1.91 | 7953 |
| 2025-05-13 | KRYS | 134.63 | 0.48 | 2.51 | 8199 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | KRYS | 168.91 | 202.8 | 115.0 | 7.58 |
| 2025-04-15 | KRYS | 169.13 | 202.8 | 109.5 | 7.58 |
| 2025-04-16 | KRYS | 164.40 | 202.8 | 102.4 | 7.58 |
| 2025-04-17 | KRYS | 168.57 | 202.8 | 114.9 | 7.58 |
| 2025-04-18 | KRYS | 168.57 | 202.8 | 109.2 | 7.58 |
| 2025-04-21 | KRYS | 161.50 | 202.8 | 99.1 | 7.58 |
| 2025-04-22 | KRYS | 168.80 | 202.8 | 119.5 | 7.58 |
| 2025-04-23 | KRYS | 165.80 | 202.8 | 104.9 | 7.58 |
| 2025-04-24 | KRYS | 169.12 | 202.8 | 114.1 | 7.58 |
| 2025-04-25 | KRYS | 168.06 | 202.8 | 107.7 | 7.58 |
| 2025-04-28 | KRYS | 169.73 | 231.2 | 111.6 | 7.65 |
| 2025-04-29 | KRYS | 170.57 | 231.2 | 110.4 | 7.65 |
| 2025-04-30 | KRYS | 169.88 | 231.2 | 108.2 | 7.65 |
| 2025-05-01 | KRYS | 165.70 | 231.2 | 103.3 | 7.65 |
| 2025-05-02 | KRYS | 166.16 | 231.2 | 109.9 | 7.65 |
| 2025-05-05 | KRYS | 162.15 | 231.2 | 103.3 | 7.65 |
| 2025-05-06 | KRYS | 139.99 | 231.2 | 75.8 | 7.65 |
| 2025-05-07 | KRYS | 136.80 | 231.2 | 104.4 | 7.65 |
| 2025-05-08 | KRYS | 137.27 | 98.0 | 79.7 | 6.69 |
| 2025-05-09 | KRYS | 132.18 | 35.2 | 69.6 | 5.88 |
| 2025-05-12 | KRYS | 139.43 | 35.2 | 92.6 | 5.88 |
| 2025-05-13 | KRYS | 134.53 | 35.2 | 70.0 | 5.88 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | KRYS | -4.56 | -0.75 | 10.98 |
| 2025-04-15 | KRYS | -4.56 | -0.75 | 10.98 |
| 2025-04-16 | KRYS | -4.56 | -0.75 | 10.98 |
| 2025-04-17 | KRYS | -4.56 | -0.75 | 10.98 |
| 2025-04-18 | KRYS | -4.56 | -0.75 | 10.98 |
| 2025-04-21 | KRYS | -4.56 | -0.76 | 10.98 |
| 2025-04-22 | KRYS | -4.56 | -0.76 | 10.98 |
| 2025-04-23 | KRYS | -4.56 | -0.76 | 10.98 |
| 2025-04-24 | KRYS | -4.56 | -0.76 | 10.98 |
| 2025-04-25 | KRYS | -4.56 | -0.76 | 10.98 |
| 2025-04-28 | KRYS | -4.56 | -0.82 | 9.79 |
| 2025-04-29 | KRYS | -4.56 | -0.82 | 9.79 |
| 2025-04-30 | KRYS | -4.56 | -0.82 | 9.79 |
| 2025-05-01 | KRYS | -4.56 | -0.82 | 9.79 |
| 2025-05-02 | KRYS | -4.56 | -0.82 | 9.79 |
| 2025-05-05 | KRYS | -4.56 | -0.37 | 9.79 |
| 2025-05-06 | KRYS | -4.56 | -0.37 | 9.79 |
| 2025-05-07 | KRYS | -4.56 | -0.37 | 9.79 |
| 2025-05-08 | KRYS | -4.56 | -0.37 | 9.79 |
| 2025-05-09 | KRYS | -4.56 | -0.37 | 9.79 |
| 2025-05-12 | KRYS | -4.56 | -2.14 | 9.58 |
| 2025-05-13 | KRYS | -4.57 | -2.14 | 9.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.2
Avg. EPS Est. Current Quarter
1.26
Avg. EPS Est. Next Quarter
1.41
Insider Transactions
-4.57
Institutional Transactions
-2.14
Beta
0.71
Average Sales Estimate Current Quarter
96
Average Sales Estimate Next Quarter
107
Fair Value
230.92
Quality Score
87
Growth Score
44
Sentiment Score
3
Actual DrawDown %
38.7
Max Drawdown 5-Year %
-53.4
Target Price
211.2
P/E
32.4
Forward P/E
15.06
PEG
0.52
P/S
11.66
P/B
3.95
P/Free Cash Flow
30.06
EPS
4.15
Average EPS Est. Cur. Y
5.88
EPS Next Y. (Est.)
10.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
37.18
Relative Volume
1.02
Return on Equity vs Sector %
-11.1
Return on Equity vs Industry %
5.8
EPS 1 7Days Diff
-1.8
EPS 1 30Days Diff
-1.7
EBIT Estimation
70
Krystal Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading